TENAYA THERAPEUTICS I

Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Research Leadership Updates

27 Jun 2024 16:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

18 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

14 May 2024 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

02 May 2024 16:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

18 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

18 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

27 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

26 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Underwritten Offering

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

21 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

08 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

26 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

09 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

05 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

02 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

21 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

31 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

09 Aug 2023 15:05:01 By Nasdaq GlobeNewswire